The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BBOT | N/A | N/A | N/A | +26% |
| S&P | +14.11% | +87.98% | +13.46% | +37% |
Bridgebio Oncology Therapeutics, Inc. is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Ka malignancies. The company is headquartered in South San Francisco, CA.
No news articles found for BridgeBio Oncology Therapeutics.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.42M | 0.0% |
| Market Cap | $970.37M | 0.0% |
| Market Cap / Employee | $11.98M | 0.0% |
| Employees | 81 | 0.0% |
| Net Income | -$44.76M | -2018.1% |
| EBITDA | -$48.77M | -33107.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $408.74M | 22790.5% |
| Accounts Receivable | $0.23M | 0.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $2.38M | 0.0% |
| Short Term Debt | $0.51M | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -12.52% | 0.0% |
| Return On Invested Capital | 80.47% | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$71.16M | -246467.7% |
| Operating Free Cash Flow | -$70.63M | -244595.5% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 43.89 | 32.48 | 44.19 | 52.91 | - |
| Price to Book | 1.44 | - | |||
| Price to Tangible Book Value | 1.44 | - | |||
| Enterprise Value to EBITDA | -1122.00 | -109.32 | -221.96 | -0.78 | -99.95% |
| Return on Equity | 8.1% | 3.2% | 2.5% | -13.4% | - |
| Total Debt | $0.00M | $0.00M | $0.00M | $2.89M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
